Families caring for someone with Alzheimer’s disease now have a second FDA-cleared drug for agitation, and for the first time, the option is not an antipsychotic. The agency approved an expanded indication for Auvelity, a combination of dextromethorphan hydrobromide and bupropion hydrochloride extended-release, to treat agitation associated with dementia due to Alzheimer’s disease in adults. The decision breaks a long-standing pattern in which the only pharmacological tools available for one of dementia’s most distressing behavioral symptoms belonged to a drug class that carries serious safety warnings for older patients.
What is verified so far
The FDA’s own announcement confirms that Auvelity is the first non-antipsychotic drug approved for agitation tied to Alzheimer’s dementia. The approval rests on two Phase 3 clinical trials. The first, known as ADVANCE (NCT03226522), used a randomized, double-blind, placebo-controlled design to test the dextromethorphan-bupropion combination, designated AXS-05 during development, against placebo in patients with Alzheimer’s-related agitation. The second, called ACCORD (NCT04797715), employed a randomized withdrawal and relapse-prevention design to evaluate whether patients who initially responded to the drug maintained their improvement over time.
The ADVANCE study, listed on ClinicalTrials.gov, enrolled adults with probable Alzheimer’s disease who exhibited clinically significant agitation. Participants were randomized to receive either the active dextromethorphan-bupropion regimen or placebo over several weeks. According to the registry summary, the primary outcome focused on changes in a standardized agitation rating scale, with secondary measures capturing global clinical impression and functional outcomes. The trial’s structure – including blinding, placebo control, and predefined endpoints – underpins the FDA’s conclusion that the drug exerts a measurable effect on agitation symptoms in this population.
The ACCORD trial, registered under NCT04797715 and described in its trial record, followed a different strategy. Patients first received open-label treatment with the drug combination; those who showed a clinical response were then randomized either to continue the medication or switch to placebo. Investigators tracked the time to relapse of agitation symptoms as the primary outcome. This design is intended to answer whether benefits persist and whether discontinuation leads to a meaningful return of agitation, information that is particularly important for a chronic, progressive condition like Alzheimer’s disease.
Before this clearance, the only FDA-approved medication for this specific indication was Rexulti (brexpiprazole), an atypical antipsychotic that the agency cleared as the first drug to treat agitation symptoms associated with Alzheimer’s dementia. Antipsychotics as a class carry a boxed warning about increased mortality risk in elderly patients with dementia-related psychosis, a fact that has long made clinicians and families uneasy about their use. The arrival of a non-antipsychotic alternative changes the risk calculus for prescribers who previously had to weigh a single approved option against off-label alternatives with thin evidence.
Agitation in Alzheimer’s disease is not a minor inconvenience. It encompasses verbal and physical aggression, pacing, restlessness, and emotional distress that can make home care unsustainable. It is one of the leading reasons families seek nursing-home placement, and it imposes heavy emotional and physical tolls on caregivers. A drug that addresses this symptom without the safety profile of antipsychotics represents a concrete shift in how clinicians can approach treatment, even if it does not replace the need for nonpharmacologic strategies such as environmental modifications, caregiver training, and behavioral interventions.
What remains uncertain
Several gaps in the public record leave open questions about the strength and scope of the evidence behind this approval. Full posted results tables and statistical outputs from the ACCORD trial have not yet appeared on ClinicalTrials.gov, even though the FDA relied on that study as part of its decision. Without those granular data, independent researchers and clinicians cannot fully evaluate effect sizes, dropout rates, or adverse-event frequencies from the relapse-prevention arm, nor can they easily compare those metrics against other pharmacologic or nonpharmacologic approaches.
The FDA’s press announcement references statements from agency leadership, including the Commissioner and the Center for Drug Evaluation and Research, but the public document summarizes rather than reproduces verbatim quotes in full. That limits the ability to parse exactly how regulators characterized the clinical benefit relative to existing options, such as whether they emphasized symptom reduction, caregiver relief, or potential impacts on institutionalization. Cross-referenced safety and drug-interaction data from the agency’s accessdata portal and MedWatch system for the new indication have not been fully linked or extracted in the press release, meaning prescribers will need to consult the updated DailyMed labeling for dosing, titration, and contraindication details.
Patient-level outcome metrics and caregiver burden measures that likely informed the FDA’s decision also lack primary source excerpts beyond trial registry summaries. Whether Auvelity meaningfully reduces caregiver distress or delays institutional placement are questions the trial registries do not answer on their own. Those endpoints would require published peer-reviewed manuscripts or FDA review documents that have not yet surfaced publicly. Until such materials are available, outside experts must infer broader quality-of-life effects from the reported agitation scale outcomes rather than from direct evidence on caregiver or healthcare utilization measures.
A separate question involves real-world uptake. Whether this approval will lead to a measurable decline in new antipsychotic prescriptions for Alzheimer’s agitation depends on insurance coverage decisions, formulary placement, and clinician familiarity with the drug. Medicare Part D prescription data over the next year will offer the clearest signal, but that data lags by months and will not be available for analysis until well into 2027. In the meantime, anecdotal reports from memory clinics and long-term care facilities are likely to shape early perceptions of how often the drug is used and in which patient profiles it is considered most appropriate.
Safety in broader practice is another unknown. While the ADVANCE and ACCORD trials provide controlled safety data, real-world patients often have more comorbidities and concomitant medications than those enrolled in clinical studies. Postmarketing surveillance and spontaneous reports will be crucial to detect rare adverse events, drug interactions, or patterns of off-label use, especially given that bupropion and dextromethorphan each carry their own established risk considerations in other contexts.
How to read the evidence
The strongest evidence backing this story comes directly from two categories of primary sources. The FDA’s press announcement establishes the regulatory decision, the scope of the new indication, and the agency’s position that the benefit-risk profile supports use in adults with Alzheimer’s-related agitation. The ADVANCE and ACCORD trials, as summarized in their registry entry and the corresponding withdrawal-study listing, define how the drug was studied, which patients were included, and what outcomes were prioritized.
For clinicians, the key interpretive step is to align those trial populations with the patients they see in practice. The registry documents outline inclusion and exclusion criteria that may differ from everyday cases, especially in terms of medical comorbidities, concomitant medications, and severity of cognitive impairment. Readers should also note which agitation scales were used, how large the observed differences were, and over what time frame benefits emerged, even if the exact numerical results are not yet fully tabulated in the public record.
Families and caregivers, meanwhile, may reasonably focus on practical questions: how quickly symptoms might improve, how the medication is taken, and what side effects to watch for. Those details are best drawn from the updated prescribing information and discussed with a treating clinician who can weigh potential benefits against individual risk factors such as cardiovascular disease, seizure history, or polypharmacy. Non-drug approaches remain essential, and Auvelity should be viewed as one component of a broader care plan rather than a stand-alone solution.
As more data emerge – through peer-reviewed publications, detailed FDA review documents, and real-world utilization studies – the picture of where this drug fits in the treatment landscape will sharpen. For now, the approval marks a notable milestone: an evidence-based, non-antipsychotic option for one of Alzheimer’s disease’s most challenging behavioral symptoms, grounded in late-stage trials but still accompanied by unanswered questions about long-term outcomes, safety in routine practice, and its ultimate impact on how dementia care is delivered.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
